Thrombolytic treatment and complement activation

A. Agostoni, M. Gardinali, D. Frangi, M. Cugno, C. Cafaro, L. Conciato, C. Sponzilli, E. Salmoirago

Research output: Contribution to journalArticlepeer-review


Details of possible complement activation in acute myocardial infarction (AMI) and the in vivo effects of fibrinolytic agents on this activation are not yet known. We measured complement activation in 40 patients with AMI: 20 were treated with streptokinase, and 20 did not receive any fibrinolytic agent. Anaphylatoxin C4a, C3a and membrane attack complexes SC5b-9 increased about 10-fold (p <0.0001) during streptokinase infusion. These were no increases in complement catabolic products in AMI patients not treated with streptokinase. Significant transient leukopenia (-29.5%, 7.0 SEM, p = 0.001) and a drop in systolic pressure (-29%, 3.4 SEM, p <0.0001) occurred after 15 min of streptokinase infusion simultaneously with the peak of anaphylatoxins in plasma.

Original languageEnglish
Pages (from-to)178-179
Number of pages2
JournalAnnali Italiani di Medicina Interna
Issue number3
Publication statusPublished - 1994

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Thrombolytic treatment and complement activation'. Together they form a unique fingerprint.

Cite this